Plasminogen Activator Inhibitor Antigen, Plasma
Use
This test is useful for identifying hereditary elevation or deficiency of plasminogen activator inhibitor type 1 (PAI-1), determining the risk for veno-occlusive disease associated with bone marrow transplantation, and serving as a prognostic marker for the occurrence or recurrence of thrombosis. It plays an important role in the regulation of fibrinolysis, where elevated levels are associated with a predisposition to thrombosis, including veno-occlusive disease post-bone marrow transplantation. It also aids in the differential diagnosis of impaired fibrinolysis.
Special Instructions
Not provided.
Limitations
The PAI-1 level exhibits diurnal variation, with the highest levels occurring in the morning. Levels increase during pregnancy and decrease rapidly after delivery. The rare presence of antimouse antibodies can lead to anomalous results. Improper specimen collection and processing may lead to platelet activation and release of PAI-1, resulting in incorrect measurements. Care must be taken to remove all platelets and minimize activation during collection and processing.
New York Approved
Methodology
Immunoassay (ELISA)
Biomarkers
Plasminogen Activator Inhibitor Type 1 (PAI-1)
Protein
LOINC Codes
- 22758-7 - PAI1 Ag PPP IA-mCnc
- 22758-7 - PAI1 Ag PPP IA-mCnc
Result Turnaround Time
7-12 days
Related Documents
For more information, please review the documents below
Specimen
Plasma
Volume
1 mL
Minimum Volume
0.5 mL
Container
Light-blue top (3.2% sodium citrate)
Collection Instructions
1. Centrifuge, transfer all plasma into a plastic vial, and centrifuge plasma again. 2. Aliquot plasma into a plastic vial leaving 0.25 mL in the bottom of centrifuged vial. 3. Freeze plasma immediately at -20 degrees C or ideally, at or below -40 degrees C.
Causes for Rejection
Gross hemolysis, gross lipemia, gross icterus
Stability Requirements
| Temperature | Period |
|---|---|
| Frozen | 2 years |